Last 12 months
Inside the activity.
5 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 5 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 01:00 UTC |
Silva Raul R.EVP and CSO
|
GrantStock Option (right to Buy) · Derivative | 4,293 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001493152-26-045581 · ownership.xml · derivative · entry 1 Silva Raul R. · CIK 0001883270 · EVP and CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,293 Underlying: Common Stock · 4,293 shares Expires 2036-09-30 F1 · date: The option was granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:35 UTC |
Downey Bryan WadeEVP & Chief Commercial Officer
|
GrantStock Option (right to Buy) · Derivative | 33,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033970 · ownership.xml · derivative · entry 2 Downey Bryan Wade · CIK 0002095821 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. F2 · derivative.exercise_date: Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027. F3 · derivative.expiration_date: If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:35 UTC |
Downey Bryan WadeEVP & Chief Commercial Officer
|
GrantStock Option (right to Buy) · Derivative | 67,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033970 · ownership.xml · derivative · entry 1 Downey Bryan Wade · CIK 0002095821 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:32 UTC |
Lawrence Bryan JayDirector
|
GrantStock Option (right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033968 · ownership.xml · derivative · entry 1 Lawrence Bryan Jay · CIK 0002011767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2027 annual meeting of stockholders. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:37 UTC |
Schaffer Shane J.Director · Chief Executive Officer
|
GrantStock Option (right to Buy) · Derivative | 97,350 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033972 · ownership.xml · derivative · entry 2 Schaffer Shane J. · CIK 0001883254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,350 Underlying: Common Stock · 97,350 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. F2 · derivative.exercise_date: Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027. F3 · derivative.expiration_date: If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:37 UTC |
Schaffer Shane J.Director · Chief Executive Officer
|
GrantStock Option (right to Buy) · Derivative | 197,650 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033972 · ownership.xml · derivative · entry 1 Schaffer Shane J. · CIK 0001883254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,650 Underlying: Common Stock · 197,650 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:27 UTC |
Werth Peter J.Director
|
GrantStock Option (right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033961 · ownership.xml · derivative · entry 1 Werth Peter J. · CIK 0001883257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2027 annual meeting of stockholders. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:27 UTC |
Silva Raul R.EVP and CSO
|
GrantStock Option (right to Buy) · Derivative | 26,400 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033959 · ownership.xml · derivative · entry 2 Silva Raul R. · CIK 0001883270 · EVP and CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. F2 · derivative.exercise_date: Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027. F3 · derivative.expiration_date: If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:27 UTC |
Silva Raul R.EVP and CSO
|
GrantStock Option (right to Buy) · Derivative | 53,600 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033959 · ownership.xml · derivative · entry 1 Silva Raul R. · CIK 0001883270 · EVP and CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,600 Underlying: Common Stock · 53,600 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:29 UTC |
Hargroves Thomas JeffreyDirector
|
GrantStock Option (right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033964 · ownership.xml · derivative · entry 1 Hargroves Thomas Jeffrey · CIK 0001883231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2027 annual meeting of stockholders. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:32 UTC |
Brams MatthewEVP and Chief Medical Officer
|
GrantStock Option (right to Buy) · Derivative | 26,400 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033967 · ownership.xml · derivative · entry 2 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. F2 · derivative.exercise_date: Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027. F3 · derivative.expiration_date: If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:32 UTC |
Brams MatthewEVP and Chief Medical Officer
|
GrantStock Option (right to Buy) · Derivative | 53,600 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033967 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,600 Underlying: Common Stock · 53,600 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:29 UTC |
Callahan Jennifer L.EVP and CFO
|
GrantStock Option (right to Buy) · Derivative | 19,800 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033963 · ownership.xml · derivative · entry 2 Callahan Jennifer L. · CIK 0001883523 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,800 Underlying: Common Stock · 19,800 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. F2 · derivative.exercise_date: Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027. F3 · derivative.expiration_date: If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:29 UTC |
Callahan Jennifer L.EVP and CFO
|
GrantStock Option (right to Buy) · Derivative | 40,200 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033963 · ownership.xml · derivative · entry 1 Callahan Jennifer L. · CIK 0001883523 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,200 Underlying: Common Stock · 40,200 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:00 UTC |
Silva Raul R.EVP and CSO
|
GrantStock Option (right to Buy) · Derivative | 3,885 | $0.00 Strike: $5.47 | $0.00 |
DisclosureSEC source: 0001493152-26-031983 · ownership.xml · derivative · entry 1 Silva Raul R. · CIK 0001883270 · EVP and CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,885 Underlying: Common Stock · 3,885 shares Expires 2036-06-30 F1 · date: The option was granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended. Read SEC document |
| March 31, 2026 Filed May 8, 2026 22:00 UTC |
Silva Raul R.EVP and CSO
|
GrantStock Option (right to Buy) · Derivative | 3,422 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0001493152-26-022036 · ownership.xml · derivative · entry 1 Silva Raul R. · CIK 0001883270 · EVP and CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3.422 Underlying: Common Stock · 3,422 shares Expires 2036-03-31 F1 · date: The option was granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:13 UTC |
Patel Nilay DahyabhaiEVP, CLO and CCO
|
Tax withholdingCommon Stock | 2,086 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009721 · ownership.xml · nonDerivative · entry 2 Patel Nilay Dahyabhai · CIK 0002076550 · EVP, CLO and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,389 F2 · security: Shares otherwise issuable were withheld to satisfy the Reporting Person's tax obligations on the grant described in footnote 1 above. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:13 UTC |
Patel Nilay DahyabhaiEVP, CLO and CCO
|
GrantCommon Stock | 5,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009721 · ownership.xml · nonDerivative · entry 1 Patel Nilay Dahyabhai · CIK 0002076550 · EVP, CLO and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,475 F1 · security: Shares of common stock were granted pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended, for a portion of the Reporting Person's 2025 bonus. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 00:13 UTC |
Schaffer Shane J.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 2,959 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009722 · ownership.xml · nonDerivative · entry 2 Schaffer Shane J. · CIK 0001883254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,076 F2 · security: Shares otherwise issuable were withheld to satisfy the Reporting Person's tax obligations on the grant described in footnote 1 above. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 00:13 UTC |
Schaffer Shane J.Director · Chief Executive Officer
|
GrantCommon Stock | 6,862 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009722 · ownership.xml · nonDerivative · entry 1 Schaffer Shane J. · CIK 0001883254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,035 F1 · security: Shares of common stock were granted pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended, for a portion of the Reporting Person's 2025 bonus. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 00:13 UTC |
Silva Raul R.EVP and CSO
|
Tax withholdingCommon Stock | 1,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009723 · ownership.xml · nonDerivative · entry 2 Silva Raul R. · CIK 0001883270 · EVP and CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,645 F2 · security: Shares otherwise issuable were withheld to satisfy the Reporting Person's tax obligations on the grant described in footnote 1 above. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 00:13 UTC |
Silva Raul R.EVP and CSO
|
GrantCommon Stock | 4,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009723 · ownership.xml · nonDerivative · entry 1 Silva Raul R. · CIK 0001883270 · EVP and CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,473 F1 · security: Shares of common stock were granted pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended, for a portion of the Reporting Person's 2025 bonus. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 00:13 UTC |
Callahan Jennifer L.EVP and CFO
|
Tax withholdingCommon Stock | 6,427 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009720 · ownership.xml · nonDerivative · entry 2 Callahan Jennifer L. · CIK 0001883523 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,961 F2 · security: Shares otherwise issuable were withheld to satisfy the Reporting Person's tax obligations on the grant described in footnote 1 above. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 00:13 UTC |
Callahan Jennifer L.EVP and CFO
|
GrantCommon Stock | 15,329 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009720 · ownership.xml · nonDerivative · entry 1 Callahan Jennifer L. · CIK 0001883523 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,388 F1 · security: Shares of common stock were granted pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended, for a portion of the Reporting Person's 2025 bonus. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 00:13 UTC |
Brams MatthewEVP and Chief Medical Officer
|
Tax withholdingCommon Stock | 1,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009719 · ownership.xml · nonDerivative · entry 2 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,157 F2 · security: Shares otherwise issuable were withheld to satisfy the Reporting Person's tax obligations on the grant described in footnote 1 above. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 00:13 UTC |
Brams MatthewEVP and Chief Medical Officer
|
GrantCommon Stock | 4,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009719 · ownership.xml · nonDerivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,182 F1 · security: Shares of common stock were granted pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended, for a portion of the Reporting Person's 2025 bonus. Read SEC document |
| March 09, 2026 Filed Jun 8, 2026 23:02 UTC |
Hargroves Thomas JeffreyDirector
|
GrantStock Option (right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.85 | $0.00 |
DisclosureSEC source: 0001493152-26-027794 · ownership.xml · derivative · entry 3 Hargroves Thomas Jeffrey · CIK 0001883231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-03-09 F1 · date: This Form 3 filing was delayed due technical difficulties in obtaining the reporting person's EDGAR filing codes. The reporting person's beneficial ownership has been reported under the caption "Security Ownership of Certain Beneficial Owners and Management" in the registrant's SEC filings made since February 13, 2026. F4 · derivative.exercise_date: The option vests as follows: 50% on the six-month anniversary of the date of grant and the remaining shares on the twelve-month anniversary of the date of grant. Read SEC document |
| February 13, 2026 Filed Jun 8, 2026 23:02 UTC |
Hargroves Thomas JeffreyDirector
|
PurchaseWarrant to Purchase Common Stock · Derivative | 77,821 | $0.10 Strike: $5.04 | $7,782.10 |
DisclosureSEC source: 0001493152-26-027794 · ownership.xml · derivative · entry 2 Hargroves Thomas Jeffrey · CIK 0001883231 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Hargroves Family Investments, LLC Disclosed balance after: 77,821 Underlying: Common Stock · 77,821 shares Expires 2029-03-24 F1 · date: This Form 3 filing was delayed due technical difficulties in obtaining the reporting person's EDGAR filing codes. The reporting person's beneficial ownership has been reported under the caption "Security Ownership of Certain Beneficial Owners and Management" in the registrant's SEC filings made since February 13, 2026. F2 · shares: Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026. F3 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 13, 2026 Filed Jun 8, 2026 23:02 UTC |
Hargroves Thomas JeffreyDirector
|
PurchaseCommon Stock | 97,276 | $5.04 | $490,271.04 |
DisclosureSEC source: 0001493152-26-027794 · ownership.xml · nonDerivative · entry 1 Hargroves Thomas Jeffrey · CIK 0001883231 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Hargroves Family Investments, LLC Disclosed balance after: 97,468 F1 · date: This Form 3 filing was delayed due technical difficulties in obtaining the reporting person's EDGAR filing codes. The reporting person's beneficial ownership has been reported under the caption "Security Ownership of Certain Beneficial Owners and Management" in the registrant's SEC filings made since February 13, 2026. F2 · shares: Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026. F3 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:00 UTC |
Schaffer Shane J.Director · Chief Executive Officer
|
PurchaseWarrant to Purchase Common Stock · Derivative | 5,447 | $0.10 Strike: $5.04 | $544.70 |
DisclosureSEC source: 0001493152-26-006025 · ownership.xml · derivative · entry 3 Schaffer Shane J. · CIK 0001883254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Fountainhead Shrugged, LLC Disclosed balance after: 5,447 Underlying: Common Stock · 5,447 shares Expires not disclosed F1 · date: Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026. F3 · derivative.exercise_date: The warrant is exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules. The expiration date of the warrant is 36 months after the exercise date. F3 · derivative.expiration_date: The warrant is exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules. The expiration date of the warrant is 36 months after the exercise date. F2 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:00 UTC |
Schaffer Shane J.Director · Chief Executive Officer
|
PurchaseCommon Stock | 6,809 | $5.04 | $34,317.36 |
DisclosureSEC source: 0001493152-26-006025 · ownership.xml · nonDerivative · entry 1 Schaffer Shane J. · CIK 0001883254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Fountainhead Shrugged, LLC Disclosed balance after: 10,175 F1 · date: Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026. F2 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:00 UTC |
Werth Peter J.Director
|
PurchaseWarrant to Purchase Common Stock · Derivative | 15,564 | $0.10 Strike: $5.04 | $1,556.40 |
DisclosureSEC source: 0001493152-26-006027 · ownership.xml · derivative · entry 3 Werth Peter J. · CIK 0001883257 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Werth Family Investment Associates LLC Disclosed balance after: 15,564 Underlying: Common Stock · 15,564 shares Expires not disclosed F1 · date: Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026. F3 · derivative.exercise_date: The warrant is exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules. The expiration date of the warrant is 36 months after the exercise date. F3 · derivative.expiration_date: The warrant is exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules. The expiration date of the warrant is 36 months after the exercise date. F2 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:00 UTC |
Werth Peter J.Director
|
PurchaseCommon Stock | 19,455 | $5.04 | $98,053.20 |
DisclosureSEC source: 0001493152-26-006027 · ownership.xml · nonDerivative · entry 1 Werth Peter J. · CIK 0001883257 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Werth Family Investment Associates LLC Disclosed balance after: 117,449 F1 · date: Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026. F2 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:00 UTC |
Callahan Jennifer L.SVP and CFO
|
PurchaseWarrant to Purchase Common Stock · Derivative | 3,891 | $0.10 Strike: $5.04 | $389.10 |
DisclosureSEC source: 0001493152-26-006026 · ownership.xml · derivative · entry 2 Callahan Jennifer L. · CIK 0001883523 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,891 Underlying: Common Stock · 3,891 shares Expires not disclosed F1 · date: Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026. F2 · derivative.exercise_date: The warrant is exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules. The expiration date of the warrant is 36 months after the exercise date. F2 · derivative.expiration_date: The warrant is exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules. The expiration date of the warrant is 36 months after the exercise date. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:00 UTC |
Callahan Jennifer L.SVP and CFO
|
PurchaseCommon Stock | 4,864 | $5.04 | $24,514.56 |
DisclosureSEC source: 0001493152-26-006026 · ownership.xml · nonDerivative · entry 1 Callahan Jennifer L. · CIK 0001883523 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,059 F1 · date: Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:00 UTC |
Brams MatthewEVP and Chief Medical Officer
|
PurchaseWarrant to Purchase Common Stock · Derivative | 1,556 | $0.10 Strike: $5.04 | $155.60 |
DisclosureSEC source: 0001493152-26-006024 · ownership.xml · derivative · entry 2 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,556 Underlying: Common Stock · 1,556 shares Expires not disclosed F1 · date: Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026. F2 · derivative.exercise_date: The warrant is exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules. The expiration date of the warrant is 36 months after the exercise date. F2 · derivative.expiration_date: The warrant is exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules. The expiration date of the warrant is 36 months after the exercise date. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:00 UTC |
Brams MatthewEVP and Chief Medical Officer
|
PurchaseCommon Stock | 1,946 | $5.04 | $9,807.84 |
DisclosureSEC source: 0001493152-26-006024 · ownership.xml · nonDerivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,656 F1 · date: Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 23:00 UTC |
Silva Raul R.EVP and CSO
|
GrantStock Option (right to Buy) · Derivative | 6,625 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0001493152-26-000455 · ownership.xml · derivative · entry 1 Silva Raul R. · CIK 0001883270 · EVP and CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,625 Underlying: Common Stock · 6,625 shares Expires 2036-12-31 F1 · date: The option was granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended. Read SEC document |
| November 03, 2025 Filed Nov 10, 2025 23:02 UTC |
Downey Bryan WadeChief Commercial Officer
|
GrantStock Option (right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001493152-25-021580 · ownership.xml · derivative · entry 1 Downey Bryan Wade · CIK 0002095821 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-11-03 F1 · derivative.exercise_date: The option vests as follows: 25% on the one-year anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| September 30, 2025 Filed Nov 10, 2025 23:04 UTC |
Silva Raul R.EVP and CSO
|
GrantStock Option (right to Buy) · Derivative | 7,334 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001493152-25-021581 · ownership.xml · derivative · entry 1 Silva Raul R. · CIK 0001883270 · EVP and CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,334 Underlying: Common Stock · 7,334 shares Expires 2035-09-30 F1 · date: The option was granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 18:02 UTC |
Patel Nilay DahyabhaiCLO and CCO
|
GrantStock Option (right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.51 | $0.00 |
DisclosureSEC source: 0001641172-25-018640 · ownership.xml · derivative · entry 1 Patel Nilay Dahyabhai · CIK 0002076550 · CLO and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-07-08 F1 · derivative.exercise_date: The option vests as follows: 25% on the one-year anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 22:00 UTC |
Schaffer Shane J.Director · Chief Executive Officer
|
GrantStock Option (right to Buy) · Derivative | 199,500 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001641172-25-018479 · ownership.xml · derivative · entry 1 Schaffer Shane J. · CIK 0001883254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,500 Underlying: Common Stock · 199,500 shares Expires 2035-07-07 F1 · derivative.exercise_date: The option vests as follows: 25% on the one-year anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 22:00 UTC |
Silva Raul R.EVP and CSO
|
GrantStock Option (right to Buy) · Derivative | 51,500 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001641172-25-018480 · ownership.xml · derivative · entry 1 Silva Raul R. · CIK 0001883270 · EVP and CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,500 Underlying: Common Stock · 51,500 shares Expires 2035-07-07 F1 · derivative.exercise_date: The option vests as follows: 25% on the one-year anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 22:00 UTC |
Myers LaurieEVP and COO
|
GrantStock Option (right to Buy) · Derivative | 31,000 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001641172-25-018478 · ownership.xml · derivative · entry 1 Myers Laurie · CIK 0001883920 · EVP and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2035-07-07 F1 · derivative.exercise_date: The option vests as follows: 25% on the one-year anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 22:00 UTC |
Callahan Jennifer L.SVP and CFO
|
GrantStock Option (right to Buy) · Derivative | 64,500 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001641172-25-018477 · ownership.xml · derivative · entry 1 Callahan Jennifer L. · CIK 0001883523 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,500 Underlying: Common Stock · 64,500 shares Expires 2035-07-07 F1 · derivative.exercise_date: The option vests as follows: 25% on the one-year anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 22:00 UTC |
Brams MatthewEVP and Chief Medical Officer
|
GrantStock Option (right to Buy) · Derivative | 52,500 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001641172-25-018476 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2035-07-07 F1 · derivative.exercise_date: The option vests as follows: 25% on the one-year anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 22:00 UTC |
Silva Raul R.EVP and CSO
|
GrantStock Option (right to Buy) · Derivative | 1,000 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001641172-25-017407 · ownership.xml · derivative · entry 2 Silva Raul R. · CIK 0001883270 · EVP and CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2035-06-30 F1 · date: The option was granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 00:02 UTC |
Lawrence Bryan JayDirector
|
GrantStock Option (right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001641172-25-016179 · ownership.xml · derivative · entry 1 Lawrence Bryan Jay · CIK 0002011767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-20 F1 · derivative.exercise_date: The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2026 annual meeting of stockholders. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 00:02 UTC |
Werth Peter J.Director
|
GrantStock Option (right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001641172-25-016181 · ownership.xml · derivative · entry 1 Werth Peter J. · CIK 0001883257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-20 F1 · derivative.exercise_date: The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2026 annual meeting of stockholders. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 00:02 UTC |
Ervin Jeffrey SDirector
|
GrantStock Option (right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001641172-25-016178 · ownership.xml · derivative · entry 1 Ervin Jeffrey S · CIK 0001762163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-20 F1 · derivative.exercise_date: The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2026 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.